that drove the share price of eli lilly. katie: that is sam of bloomberg intelligence, thank you so much. we want to go back to that donald trump news we broke. we will go to kailey leinz from washington. the headline here trumped denied immunity in dce election case by appeals court. what do we know so far? kailey: this is the case the president has been making for some time that he is immune from prosecution in the case special counsel jack smith brought charging him with efforts to overturn the results of the 2020 election that he should be immune from the prosecution as a former president and that the actions he took of the united -- as president should be protected. the appeals court ruled against that saying he is not in fact immune. this decision will be on hold until february 12, six days from now so the president -- former president can appeal it to the supreme court. this does not mean this is over entirely yet. the trial in this case jack smith brought was slated to start on march 4 just last week and the judge in

eli lilly, 10% of that. you can get a lot of the other lower costs competitors as well especially if m & a space in activity you want to own a plethora of names. >> very interesting. i find all of these bio tech names, pharma names so compelling with everything going on -- >> also she said plethora. that's my wordle opening word. that's not true. >> that's way too many letters for wordle. >> that's the joke. >> oh, gosh. okay. >>> now other to spotify. the digital music streaming company posting q4 earnings that beat expectations. julia boorstin is covering that for us. what do you got on spotify? >> spotify shares surging higher, they were up a lot more. now up about 3% today. stock trading around an all-time high. this is on strong guidance and surprise profit. 37 cents adjusted earnings per share rather than the 21% share per loss. this follows the company laying off 17% of its staff in december. spotify reporting strong user growth, including a 15% increase in paying subscribers ahead of expectations. th

for example, eli lilly has a market cap 750 billion ish.ct, completely different company in the same world does $6 billion in the same revenue and has less than half the market cap. i understand the growth and all those things, that's great. in order for eli lilly to justify those types of valuation you have to go from 50 in my opinion to about 150 to $200 billion to make sense in terms of the math. now, if you think that's going to happen, stay with it. and we've been bullish on eli lilly forever, but at a certain point you have to look at it objectively. >> do you bring up the vanity aspect of the drug because you think those sales are fleeting? as opposed to someone taking it for obesity -- >> which i totally understand and i'm sympathetic towards without question. but i would be fascinated to see the break down between the people that are taking it because they're clinically obese or statisticically obese as opposed to the people that are taking it because they have a wedding in three week and they want to fit into a tuxedo and/or a dre

novo and eli lilly are in phase three.ovo's next-generation drug promised a 25% will see data la year. >> 20% of u.s. kids overweight. could be a big runway for the drugs. emily, thank you for your time. >> thank you. >>> a programming note, catch "power lunch" today diving into rare disease with scott gottleib. >>> coming up, an openai investigation over whether the company has been misleading investors. detas h silonowam altman factor into the probe. that and much more when "worldwide exchange" returns. stay with us. how am i going to find a doctor when i'm hallucinating? what about zocdoc? so many options. yeah, and dr. xichun even takes your sketchy insurance. xi-chun, xi-chun, xi-chun! you've got more options than you know. book now. what is cirkul? cirkul is the fuel you need to take flight. cirkul is the energy that gets you to the next level. cirkul is what you hope for when life tosses lemons your way. cirkul, available at walmart and drinkcirkul.com. >>> welcome back to "worldwide exchange." time for the "big mon

lilly and novo nordisk taking the world by storm.ait to see tonight's documentary about these particular drugs by my colleague melissa lee. it's called "the big shot. and it's on tonight at 10:00 p.m. since this is "mad money" i want to talk about the best way to invest in this amazing wave sweeping the globe first as the documentary shows these drugs are big, and i mean really big in this country more than a third of our population's obese, more than 2/3 overweight that's a lot more than the 5 billion people that are currently taking these drugs second, what matters for the most isn't demand, it's supply eli lilly's the only company that can afford to provide the supply of these drugs and they're doing it by building necessary plants novo nordisk doesn't even have money to do it nor can viking therapeutics everyone's so excite about even though their drug's only in phase two and their share offering today cratered the stock. that's why i stand by the idea i've been hearing from legendary investor ken langone for a long time eli lill

eli lilly's drugs out there right now, more effective for weight loss. we have to have some exposure but i told you one of my concerns was if i wanted to get ozempic without a prescription i could google it and have it at the front door in three days. stuart: i want to talk in video. it cost $700 a share. a lot of people say it is going to 900 or thousand or 1100, takes a strong stomach to buy a stock that has gone straight up to $700 a share. would you buy it? >> i own it but some of the things you need to do with microsoft, apple, all these stocks, you need to be prudent. you should have owned a year ago, trimming on the way up. we haven't removed nvidia recently, have no intention of doing is that but if it goes from 700 to 800, 900, a thousand, i told you last year, it would be in video. it doesn't mean there are opportunities to add to it on pullback but when it goes from 700 to 800, 900, you have to be smart, disciplined and take chips off the table. stuart: it is on adept at the moment at 680. consider that a dip. we will see you later. i want to

what about eli lilly? bank boosting for lilly to 950 from 805. >> it's 741 billion is the market cap. it reported february 6, the response to earnings has been nothing but positive. the stock has not corrected at all since that earnings report. and really right now the catalyst for this stock is the momentum funds going in and buying it. they have a 5% weighting now to eli lilly. it's a powerful force. it's being pushed higher now on that momentum but the fundamentals are clearly in place from a company that trade like a biotech. >> shannon, there's been so much attention on these drugs and eli lilly a beneficiary. if you're looking to health care or maybe could expand it out to biopharma, what would you suggest? >> it feels like the cholesterol drug franchises like lipitor and pfizer and the other drugs put out at the time. it's a very large addressable market. the difference with lilly, and i would speak to some of the comments joe made, the pipeline. they have other really strong drugs in their pipeline

♪ ♪ ♪ >>> the veterinary medicine place, off by eli lilly lily in 2014.s footing for years the stock struggle but in last few months more than doubled off its lows. it's kind of a mixed update. a two-cent earnings myth. it came on strong, the pet business while that math. managements for your forecast was modeled on my expectations but it fell short. initially the stark opened down 6.5% response, it snaps back nearly finished flat, down 11 cents. what on earth is going on here? let the president of elanco animal health, mr. simmons welcome back to mad money. >> great to be here jen thank you. >> it was a funny day, because people like me were like oh my god, is this a setback? but actually when the smoke cleared you are a second quarter 5%. the use did some great things because you saw some apple and you heard me say you need some debt pay down. we had some blockbusters that could ignite earnings for several years to come. >> yes you just hit on all the key factors. i think the second half of 23 saw a lot of proof points of strategies working. two quarter

coming up, we will talk about the obesity drug battle as eli lilly estimates stronger sales of its shot, more than wall street inches abated. stick with us -- more than wall street anticipated. stick with us. this is bloomberg. ♪ (♪♪) we're lucky to have this team working for us. our therapists give their all each day, by helping those who need it most. we take great pride not just in the job our team does, but in them as people. our people. and while we're in the business of taking care of others... it's important our therapists know that with benefits from principal, they're taken care of too. (♪♪) sonali: this is "bloomberg markets" and i'm sonali basak. time for the stock of the hour. shares of eli really -- of eli lily are rallying after 2024 topped expectations. excitement for the weight loss business has made it the -- madison muller covers the industry and joints me now. it is interesting to see what the cfo said to investors, that is taking on the most ambitious expansion agenda in the company's history. how expensive will that be? madison: that was the focus of today's call es

we could say today, eli lilly set up for the 15% to 20% drop we saw before.u're going to get a better entry point. i'm not saying go short, i'm saying, you have to find a place to buy it and you're going to get a better entry on the downside. >>> coming up, time to just sell it? nike stomping higher today, but the chart master thinks this one might be a sinker. refa ce.ke theas bring your trades into focus on thinkorswim desktop with robust charting and analysis tools, including over 400 technical studies. tailor the platforms to your unique needs with nearly endless customization. and track market trends with up-to-the-minute news and insights. trade brilliantly with schwab. xfinity rewards presents: '1st and 10gs.' xfinity is giving away ten grand to a new lucky winner for every first and ten during the big game. enter daily through february 9th for a chance to win 10gs. with the ultimate speed, power, and reliability the xfinity 10g network is made for streaming live sports. because it's only live once. join xfinity rewards on the xfinity app or go to xfin

. >> your picks are eli lilly and amazon and alphabet. what do you like? >> they are all strong. if you look at the last quarterly reporting, specifically with eli lilly, 20% revenue growth over the year over year. 28% of the last quarter. they have the drug that was just approved by the fda last november which could be the most lucrative drug for weight loss of all time. zepbound. the eli lilly is making strategic investment to ramp up production to take advantage of the market which is billions. >> robert schein, thank you. >> thank you. >>> let's check on the morning's top corporate stories with silvana henao. silvana, nice to see you. >> contescontessa, good morning. let's get you headlines. apple is ramping up development of new generative a.i. features for the programming software similar to microsoft's copilot. bloom bberg says it will releas to third parties this year to complete lines of code and write code to test apps. executives demonstrated the new a.i. features late last year. >>> nike is cutting 1,600 jobs. that is 2% of the work force. the company is will looking

they go shooting out resources from the pocket of manufacturers such as pfizer and eli lilly. also, i want to know to weight loss shots range, all right, as the latest weight loss products, the pre flight, eli lilly in the us, you've done. they will all look to develop something that might not infringe on the other's problems because that has a different composition. and the issue is because, um, if people become healthier overall because they ate more healthily as a result of the shot. and then that would promote health, i would cost to companies that profit from people being ill. i mean that's definitely the case and the cost of discount right now. and the next 10 years, the market is expanding still what people are getting for it need. and no one wants to get a, we're having difficulties giving up to the drilling to market. so there's, there's no street. when the action runs out, then you will see as a shop driving prices in the us, a monthly dose of, as i'm pick costs around a $1000.00 without health insurance on affordable to many of his health insurance companies in euro

right, as the latest weight loss products, preflight, eli lilly in the us, you've done ali. they will all look to develop something that might not infringe on the other's problems because that has a different composition. and eventually, as long as people become healthier overall because they eat more healthily as a result of the show. and then that would promote health. would cost to companies that profit from people being ill. i mean that's definitely the case. that's the cost of discount, right now, on the next 10 years, the market is expanding, still won't be looking for it. and no one wants to get a, we're having difficulty giving up to the drilling to model. so there, there's no switch them put when the action runs out. then you will see a shop proven prices in the us, a monthly joseph, as i'm pet costs around a $1000.00 without health insurance on the affordable too many budget health insurance companies in europe cover the costs. pharmaceutical company sales will continue to rise ever and ventured something incorrectly or sold a piece of clothing together the along t

eli lilly could quintuple their earnings. now is the stock overbought? absolutely. don't think so and for that reason you have to put it in the dow given the fact it is one of the dominant stocks in the single biggest industry in the u.s. economy, healthcare. the fact it is not there every single day is a miss. will change our lives. >> strong endorsement for eli lilly. boris, always great to see you, sir. boris schlossberg. >>> still ahead, apple releasing a sports app. sign me up. it looks to become a sports btietng powerhouse, next on power lunch. now earns 5% apy. 5% apy? that's new! yup, that's how you business differently. fresh, warm hot dogs! when i'm not selling hot dogs, i invest in a fund that advances innovations like robotics. fresh, warm hot dogs, straight out of my torso! one for you, one for you. oh, you're a messy one. cool, right? so cool. anyone can become an agent of innovation with invesco qqq, a fund that gives you access to nasdaq-100 innovations. hot dogs! fresh, warm hot dogs! before investing carefully read and consider fund investment obje

eli lilly overtook tesla's market cap. that's about demand. there's demand for the drugs.oven to be more effective at weight loss than ozempic. i think you have to have exposure to these glp-1 stocks. my concern, cheryl, is there's not a lot of moat, believe it or not, around these glp-1 drugs. if i went to google right now and typed in buy semi glutide or ozempic, there will be hundreds of pharmacies that will sell it to me immediately and it will be delivered to my doorstep in three days without having a prescription. that's my biggest concern. i don't think i would go all in on these. i think i would be a little you prudent about making sure you have some exposure but not over doing it. cheryl: you want something that's fda regulated and safe. you're talking about safety. it goes back to the point that whether it's pfizer or eli lilly or any pharma company, they've got to pick be up the pace on this. there's production and supply issues. kevin, anything else you're watching right now? >> i believe in the healthcare space, we're going to see continued momentum in the m&a

we enjoy right as the latest weight loss products approved by eli lilly. in the us you've done that. they will look to develop something that might not infringe on the other's problems because that has a different composition in the nation. as long as people become healthy overall because they ate more healthily as a result of the shot. and then that would promote health. i would cost to companies that profit from people being l. i mean, that's definitely the case. that's the cost to discuss. right now in the next 10 years, the market is expanding, still more people are getting a new one in order to get a we're having difficulty giving up to the room to monitor the trip. but when the action runs out, then you will see as a chaperone in prices, in the us, a monthly dose of as i'm pet costs around a $1000.00 without health insurance on the affordable to many of his health insurance companies in europe cover the cost pharmaceutical company sales will continue to rice ever ventured something incorrectly or so the piece of clothing together is the wrong wayne.

eli lilly jumping after quarterly results this morning. estimates on nearly all metrics. joining us now with more, jeff meacham, bank of america securities senior pharmaceuticals analyst. jeff, what's the real franchise here? eli lilly was going to be the preeminent sort of mental health company for a while, remember? and suddenly, that's not what it is. what is it? a diabetes/weight loss company? >> that's a good one, joe. thanks for having me. you're right. alzheimer's was by far one of the more interesting pipeline assets for, i don't know, five years ago, but for sure, this story has changed to diabetes, obesity, just to give you some context. mounjaro plus zepbound was approved 18 months ago and here we stoand today at a $10 billio revenue run rate just now launching in obesity. so it shows you the growth has been aggressive by far in metabolic disease, less so relative to alzheimer's. what's the eventual market opportunity for this? is it going to be -- is there anything that could derail these -- obviously, we're anticipating a lot

again, this is eli lilly. can you imagine where the stock would go if they give them a thumbs up in the next few weeks? and those using the authentic stupidity co-pilot dumped the stock furiously because others were dumping it. something they barred and flagged to me as being dump as wood. and today the stock rallied $20 back. second example. people jumping in to buy shares in new york community bank the other day to find out the company lost their chief risk officer and chief audit executive, and they had not disclosed it in time, which is a part of the course from this outfit. given 60% of the bank loan book is in the now despised high risk commercial real estate category according to morgan stanley. it took degenerative national stupidity on this one. i know that they use deep learning to catch the bad guys. what i didn't know, some traders use small language bottles to figure out what stocks to sell. they always seem to dump the cybersecurity stocks even though this might be the strongest theme of our you.

eli lilly have become a weight loss company.e the eighth largest company with a market cap of $670 billion? the eighth largest company. two such drugs, mounjaro and -- [inaudible] recently approved by the fda brought in since early december $170 million in sales. mounjaro, $2.2 billion in sales in 3 months' time. these are enormous numbers. ely eli lilly says they're using the active ingredient for other problems like liver disease, and they're getting solid results. this is a high class problem. they say demand will exceed supply for all of 2024. they can't make the drugs enough. stuart: we're going to change the subject and the area completely. spirit aeroprosystems, big customer for boeing. lauren: their largest customer. if the faa chief says there needs to be permanent inspectors at spirit as well as boeing, and after a boeing -- their forecast because of the issues with the fuselages and the drill holes, spirit aerosystems has too. stuart: spotify. lauren: the stock up 10.5%. monthly active users rose by 23%, and the premi

looking at eli lilly, they could have their pill on the market. is that a similar timeline for you?use we have the clinical data but i would also say that there is other interesting data. we just announced exciting is one data. we believe we have an interesting portfolio that we can successfully brings the market over the years and get closer to different preferences that are there. >> it is great to see you in person. we really appreciate your time. that is the ceo of your organs and. does the earnings out after the battle. we dig into that company, next. ♪ that first time yoke a . i made that. with your very own online store. i sold that. and you can manage it all in one place. i built this. and it was easy, with a partner that puts you first. godaddy. sales tax automatically. avalarahhhhhh what if tax rates change? ahhhhhh filing sales tax returns? ahhhhhh business license guidance? ahhhhhh -cross-border sales? -ahhhhhh -item classification? -ahhhhhh does it connect with acc...? ahhhhhh ahhhhhh ahhhhhh katie: we are watching disney. investors are eager to hear any hints of affabi

eli lilly has a similar formulation.be left out constantly it's hard to build all the plants you need to get this. you have david ritz, who is very good, who knows how to build the plants. viking has to do a tie in -- >> we need to show shares of viking therapeutics. it's a $6 billion company. >> up 26 points. >> bktx back in the control room. the stock this morning, jim told you on the back of these phase 2 trials for its weight loss drug. wow. >> yeah. well look, enjoy it while it lasts. there's many challengers. amgen was a challenger. f pfizer was a challenger. >> amgen is down 3% today in part on this? >> it is. amgen is going further away. people were hoping they had a once a month injectable and they thought they had a pill. everything that viking has dave is working on at lil and has something. phase two is very, very hard, very expensive. >> so while investors may be joysing at viking's science. >> unless pfizer comes on and buys them which is unlikely. >> i don't know. you never know. get into the weight loss d

and yet these are the companies that compared to the super six or eli lilly or tesla? that's just insane periodically because of my age i get to pull rank i was there right in the scrum bringing the profitless the street.com public to glowing reviews with a billion-dollar valuation and no plan to stop losing money i didn't like this i listened, i watched i heard i wrote it all down in confessions of a street addict begging the underwriters not to let it go so high please because we couldn't of equal what the market was saying we could do given our hideous losses and the notion of comparing any of these modern megacaps to the best in the dotcom era is fatuous, lacking even a shred of rigor. here's the bottom line you may think these megacap stocks are now wrongly valued versus the rest of the market. i say you have to value them somehow someway and you can't just give them a gigantic bigness haircut because of their sales or earnings. but if you're saying these companies remind of you of 1999 to do you i say give me a break. i know who you were. you were probably in thi

i'm not just talking about the huge winners like eli lilly or amazon. these days there are so many solid gains, 10% or more, created daily around here. it's pretty astounding in itself. i ran a screen of the s&p 1500 to see how many stocks have given a 10% gain just since tuesday's close. why does this matter? because even if you take profits on the 10% gain and pay the taxes you're going to beat what you would have earned in a year of leaving your cash on the sidelines. i don't denigrate anything that gives you a sizable return. but can you at least admit you might be missing out on some huge gains if you steer clear of the stock market? notable gains from the small sample so you can see how broad the rally really is despite what you may hear in the press, the chattering heads, whatever. you have this regenix which is a drug company that revealed it might have something against duchesne muscular dystrophy. it's a terrible disease. very rare. meaning they can charge very high prices for any treatment. that stock vaulted nearly 25% in two days in respons

we could easily become the eli lilly fund because it becomes dominant.y to do at all times is make it so that we do not swing from one company. and that is what makes us feel like you have to do some trimming. >> i think there's a difference between trimming and selling. and if we've learned anything from 2022, it's that even the best companies in the world with the best products and great sheet management no one was immune to a significant pullback so if you an avoid something like that, then, it favors trimming, even if it is such a great company. >> vertically pit, i would like to say, there's always a market, and i'm >>> right now on last call, the moment all you investors have been waiting for. while the stakes cranked up ahead of nvidia's earnings . >>> hollywood reacts to open a and open ai. >>> new streaming rivals may be looking to date. >>> the return of our exclusive insider buying segment. there's been a lot

eli little lilly is exceeding tt this point.esla is asking manager which jobs are critical, igniting fears of he potential layoffs there. mark, your thoughts on this discrepancy. he eli lilly, higher market value than tesla. >> it's wild. what you're seeing play out here is a complete polar opposite in demand. you've got eli lilly with monjaro which is supposed to be more effective than ozempic for weight loss. they're rolling out zepboung for people that are trying to lose weight with a bmi that exceeds 27, which is a lot of people out there. there's a lot of demand for the drugs, those are game changing drugs. a lot of people are interested, trying to see how it can help them in many ways outside of weight loss. you look at the ev landscape which is a challenged landscape. you had 38 auto dealerships at the end of last year write a letter to president biden asking him to roll back ev mandates because they had a bunch of evs sitting on their lots that they couldn't sell. there's no demand for evs. on top of that, with regards t

caroline: you are doing it in combination with eli lilly.how much you do go hand in hand with the older guard, those already bringing these two market? kristen: that is a great question. our drug which improves muscle and metabolic function is in competition with these drugs that are currently delving. from the trial, we are going to become by our drug together with eli lilly's drug to see if we can increase the quantity of weight loss. there will give more weight loss as well as the quality of weight loss to help it be healthier with a better balance. importantly, our drug -- the feature here is instead of having to inject yourself, have a weight loss pill that achieves the weight loss you need in a healthy way. ed: what is your biggest cost? what are you good to spend on headcount or software? kristen: the largest cost is the clinical trial. be require hundreds of people taking good drug months at a time, look at a conference if battery of tests so that the software where the headcount is not the cost either. caroline: tell us how the tria

that's how good eli lilly is.ou know, obviously, these companies are not going to give up, but that's how great the study is. these are remarkable numbers out of lilly and it's such a good drug. it has to go higher. this is a disease that is a death sentence for a lot of people. everyone was working on it. it is -- they'vewon. they've got it conquered. it's incredible. >> fascinating. >> tonight you mentioned simon. >> i have simon. again had a great number. gives you great yield. i have dave getland who rang the bell for carrier. did it do as well as train? we'll talk about it. maybe it should be up. chipotle, been recommending that stock since 400 when they had the airborne illness, any staunt restaurant could have had it. the cfo maybe he replaces rich, now that rich retiring from costco which is devastating. >> curious to hear about pricing after mcdonald's yesterday. >> absolutely. and that was a very throw yourself on your -- a discouraging comps call, mcdonald's. when talking about trading down from mcdonal

speaking of fresh highs, a number of firms hitting highs, eli lilly, cigna, uber among them.red for boeing and spirit aerosystems, boeing found more issues with the 737 max jets. much more ahead and details later in the show. let's start with some of the market moves right now. i mentioned yields. if you look at just widen out a little bit on the six-month 10-year yield chart, so we got to super low yields, at least for the current cycle, below 4%, and then since powell came out last week after the news conference we got strong jobs data, better services number, with higher prices paid, little bit firmer university of michigan expectations on 10-year inflation rates, 10-year yield is moving up. that takes the dollar with it. the dollar is now at multimonth highs. some other major currencies, dxy tracks higher and pushes out the march cut, right. powell firmly did that. he doubled down on that on his interview on "60 minutes." may from 100% to basically a coin flip. people are eyeing the second half of the year for the first cut. chair powell did speak on "60 minutes" and reit

brian belski, you bought more eli lilly.said, the stock has been a juggernaut it's up almost, feels like every day, and so does the optimism. >> some good news surrounding us we've owned lily for a number of years, scott what we've done the last couple years is unwound a lot of our other pharma stocks and put it into lily being more concentrated and then through that we got lucky with respect to the weight loss drug side of things at the end of the day, health care is such an important sector last year a lot of people were bullish on the sector. and given the fact it's much more diversified, i think you have to have that holding in pharma devices and some of biotech. lily has been long term. now it's the largest >> it is up over 6%, health care, at that being. do we think -- okay, let's say you just refuse to buy tech, weiss, if you refuse to buy comp services at this point, you don't want to buy tech what about health care? is this the natural place to go and look now or what >> health care is kind of interesting. i just st

all right, lou are, start with eli lilly. >> yeah.but i'm here to say the stock probably keep going up because we're at the early innings of this weight loss drug phenomenon, and eli lilly is going to be the leader here. and i say that based upon our analyst pipeline, and they have something unique, and that is a small molecule, a pill, that could have the same imp pact if as the injectable. so this would give them, one, a cost advantage because, obviously, a pill is much cheaper and affordable, and it can also give them the same benefits. it's easier to administer. this is something not many if people know about -- stuart: and who wants an injection when you can have a pill? >> exactly. i'm not sawing this is the solution to the obesity crisis, but a lot of things that happen afterwards start because of our dietary the issues. if we can get people on the right path with an injectable or a pill, that's a positive thing. there's side effects that we don't know about yet like fen-phen in the '90s. stuart: oh, i remember that. give me an

the new potential competition here impacting eli lilly and ozempic maker novo nordisk.nt. we should rook at zoom -- looked at zoom shares. the sid owe conferencing king on pace for its largest percentage increase in more than a year with. zoom proving it's more than just a pandemic era darling after reporting a fourth quarter revenue beat and announcing a $1.5 billion share buyback program. norwegian cruise line, it is sailing all the way to the top of the s&p 500 after forecasting a first quarter profit above wall street estimates. the cruise line operator cited cost control, higher ticket prices and steady demand for cruises globally, and that is enough to punch this stock 19% higher. no surprise here that the news has rival royal caribbean and carnival also floating higher. you've got carnival up 7.5%, royal carrib up 3%. >>> jetblue air aways and spirit airlines both flying a bit higher after showing they be will fight to overturn a judge's ruling blocking their $3.8 billion merger. the airlines say the u.s. district judge, quote, improperly chose to elevate the int

the s&p strength comes on the back of rallies in the megacap names, nvidia, meta, eli lilly. so, now that we've hit this big round number, where do we go from here? >> higher, mel. no, look. congratulations, i mean, for everybody bullish on the desk, everybody but me. i took the math in college for at least a day. 5,000 divided by 250, which you are not going to get, is still a 20 multiple. rachet down earnings, which are probably closer to 225, and we're looking at a market that's trading close to 22 1/2 times, which historically is pretty expensive. you can say, you know what, it's justified, the rest of the world is slowing down, united states, you want to be there, you should pay up for the growth, you should pay up on the multiple -- i'm not one of those people that believes that. >> i haven't been one of those people bullish on the desk. but when you think about what's gone on here, we talked about the multiple expansion we saw last year, the concentration of the top names in the s&p 500, really just blew out the multiple of the s&p 500. there's plenty of sectors and yo

a huge mover in the pharma space today would be viking therapeutics, shares of eli lilly competitor viking today. yes, you heard me right. after its experimental weight loss drug showed promising initial results in a mid-stage trial and for our next installment of our healthcare ecosystem series we focus on fa pharma including eli lilly, merck. is 2024 the year to the extent that 2023 wasn't of the fat drugs? >> yes, i believe 2024 continues the theme of obesity as a major theme in the pharmaceutical space. clearly the data from viking today very encouraging. it is phase 2 data and they are a few years out from phase 3 d data, not a direct competitor to lily and novo. >> land of the free, home of the fat. let's talk about lily a little bit. lily is -- does it still have the pole position hereeven against novo nordisk. >> so, yes. i think at this point it's still a due oply. we are very bullish on lily and think that both can exist in this market. the key here is the data that they have but also the manufacturing and the supply that they're able to bring to the market. remember, they invest

lilly part of this is doing the math, some of it is the art.s the growth, a company that's innovating. mag 7s by definition are the largest ones in the world. lilly fits the bill on market cap and everything else in terms of what they're doing. and you could argue it's biotech even. >> what are you thinking >> i came to the same conclusion, although i think i followed the batch more of arts as opposed to batch more of sciences like my colleague tim listen, i think when you're looking for a mag 7 definition, something with growth potential, margin of safety, brand awareness, and so the rest of these companies essentially have been transformative in what they offer the end user and i think lilly fits squarely in that. whether the market cap was there, i would make the argument that it has the upside potential and fit there and be toe to toe with the other six. >> coming up, snap, eli lilly, paypal, pepsico are reporting earnings next week we asked our traders for the names they're watching you'll have to find out after the break. >>> and here is

shares of eli lilly surging 6% ahead of its earnings tomorrow. will the results deliver another shot to the arm of this red-hot pharma stock? or has it come too far to fast. >>> and later, a cosmic move for a cosmetics company and a media mogul confirms his interest in paramount. the headlines are coming up. i'm melissa lee, coming to you live from studio b at the nasdaq. on the desk tonight -- tim seymour, dan nathan, guy adami, and kristen bitterly. >>> we start off with what seems to be unbridled euphoria in a handful of names. take a look at shares of nvidia, surging almost 5% today. the shipchipmaker is up 40%, ad half a trillion dollars in market cap in that time. meta on a hot streak. jumping almost 15% in the past five sessions, even with today's losing day. the social media giant gained nearly $200 billion in market cap just on friday after a blowout earnings report. so, what do you make of this euphoria, what seems like it, guy? >> well, it's remarkable. goldman sachs reiterated their buy in nvidia. today, it traded 1.5 times normal vol

a new study shows that eli lilly's drug zepbound could lower blood pressure >>> the cdc is relaunchingature former smokers. >>> picking your noise could increase your risk of developing alzheimer's disease. exposing the brain to path jens this way could lead to production that causes the disease. >>> a planet has been discovered, the exoplanet could be the right temperature for liquid water to form "early today" will be right back lyod" lle gh back. did you know... 80% of women are struggling with hair damage? just like i was. dryness and frizz could be damaged hair that can't retain moisture. new pantene miracle rescue deep conditioner, with first-of-its-kind melting pro-v pearls... locks in moisture to repair 6 months of damage in one wash, without weigh down. guaranteed or your money back! for resilient, healthy-looking hair... if you know, you know it's pantene. nature's bounty hair growth. clinically shown to help grow thicker, fuller hair with just one capsule a day of advanced hair complex. conquer hair thinning... ...and fall in love with your hair all over again. only from nat

but then you had the eli lilly which was up 10% because everybody seems to want those weight loss drugses. but on the other side is, fmc which does pesticides, had a problem with weather in brazil, and that stock was down almost 20% but alternatives in general have been good. we're beating by more than we typically beat, and it looks like we're going to have earnings up about 9 during the fourth quarter. -- 9%. jack: so when tech stocks start jumping ooh 50% in the week, technicals say the market's a little overbought. i think it's wise to get a little nervous right now. are we due for a pullback. >> the stock market can't go up forever. a lot's going to depend on the in connection week. we're looking for economic indicators, we want to see what's happening with inflation. >> i mean, we are getting the cpi this week, so that's an interesting one to watch. apparently, we did get revisions today, and those actually showed that can december still remains pretty calm, and we're expecting that to be the same. jack: hope so. >> and, of course, we're going to look for more earnings. it's not o

eli lilly says it supports bipartisan legislation capping prices at $35 for everyone.ould have a cap. >> reporter: then she'd know cassie could always afford the life-saving medicine she'll need. roxana saberi, cbs news, mechanicsville, virginia. >>> a bomb threat forces a united a lines jet to >>> tonight the fbi is investigating a bomb threat aboard a united airlines jet. a flight from newark had to make an emergency landing in chicago this morning after a fake bomb note was found in a bathroom. passengers had to be temporarily evacuated. and that came one day after an american airlines flight to chicago was forced to turn back to albuquerque after a man had to be subdued by passengers after he allegedly tried to open the plane door mid flight. >>> several days of heavy rain triggered landslides today in southern california. a stretch of the pacific coast highway was closed in both directions along with several other roads in the malibu area. beverly hills ended up with 4 inches of rain in five days, while more than 8 inches fell in the santa monica mountains. >>> fi

lilly. what do you say to people who say 12 is too young to put a child on a weight loss medication >> yeah, i think that it's about education for the family, because i think there's a lot of perception about using the medication, about for really appearances. that's not what we're here to do what we're here to do is to help your patient, a 12-year-old be healthy. >> reporter: but there are possible side effects like nausea, vomiting, and abdominal pain doctors at uc irvine say they're worried these drugs could affect kids' growth from undereating or be abused by those with eating disorders or in sports some also question whether kids need to use these drugs long-term. what do you say to people who think the data is not there, that we don't know the long-term effects for young people >> yeah, so these medications, i think are reassuring in that they've been around over a decade. >> reporter: in a statement, wegovy's maker novo nordisk says its studies found their medicines did not appear to

go sell eli lilly. that's another one people want to sell.hink general mills is shaking in its proverbial boots. >> that piece says food hasn't taken this much income in 30 years and they quote steve kaelin saying, it's hard to point to eras in which food prices go down and stay down >> the supply chain is really drastic. everything costs more. the transport really just gutted a lot of people. you look, and you look at where's the two ruby red grapefruits for $3 when it's now $6 how did this happen? the answer is that everybody let it happen and someone is going to have to hurt their gross margin, and the company's going to hurt their gross margin are the companies that are going to lose sales to the empire that is eli lilly that people don't -- are all -- no one -- doug wouldn't go there. no one is willing to admit that the 7 to 10% of the people who are going to be taking these things just don't want those foods anymore. pepsi was up 3%. i think that raymond is amazing, but if you can eat just one, then you're going to eat just one. >> the

and a paid consultant for weight loss drug makers novo nordisk and eli lilly.oo young to put a child on a weight loss medication? >> yeah, i think it's about education for the family, because i think there is a lot of perception about using the medication for really appearances. that's not what we're here to do. what we're here to do is to help your patient, a 12-year-old be healthy. >> reporter: but there are possible side effects like nausea, vomiting and abdominal pain. doctors at uc irvine say they're worried these drugs could affect kids' growth from undereating or be abused by those with eating disorders or in sports. some also question whether kids need to use these drugs long-term. what do you say to people who think the data is not there, that we don't know the long-term effects for young people? >> yeah, so these medications i think are reassuring in that they've been around over a decade. >> reporter: in a statement, wegovy's maker novo nordisk says its studies found their medicines did not appear to affect growth adding that prescribing an anti-obes

>> biotech, merck, eli lilly.me tax positions with holdings and that's another move that george soros made. you are seeing biotech with family offices. sonali: were talking about tiger, viking, how are they positioning in this environment? >> they sold out of their stake in meta entirely. i think many reasons the stocks have done well for a while and they wanted to some profits. it's interesting to see viking got out of that entirely. sonali: what about an aggregate? were there any leanings that you think are interesting among the filings last year? >> this data is backwards looking. through the end of december, it's not well-positioned at the moment but we saw a lot of amazon, nvidia. these trends we see at this time of year but keep in mind, we don't see short positions and it is limited in the hedge fund universe. sonali: thank you so very much. on the hedge fund community. that does it for us out bloomberg markets. nasdaq is up .1%, nasdaq trying to break into the green. we have the two year yield below the 4.

. >>> mentioned eli lilly. want to show you this chart.chart up 134% year to date. higher again. morgan stanley takes its price target on the stock from 950 to 805. wonder if it can be the first trillion dollar stock. they say current valuations understate how much revenue this company will get from its diabetes and glp-1 revenues. zepbound, mounjaro, trulicity. dow down 116 and the s&p down about 0.3%. back in two minutes. fresh, warm hot dogs! when i'm not selling hot dogs, i invest in a fund that advances innovations like robotics. fresh, warm hot dogs, straight out of my torso! one for you, one for you. oh, you're a messy one. cool, right? so cool. anyone can become an agent of innovation with invesco qqq, a fund that gives you access to nasdaq-100 innovations. hot dogs! fresh, warm hot dogs! before investing carefully read and consider fund investment objectives, risks, charges, expenses and more in prospectus at invesco.com. were you worried the wedding would be too much? nahhhh... (inner monologue) another destination wedding?? why

eli lilly says it supports bipartisan federal legislation capping prices at $35 for everyone.> every insulin should have a cap. >> reporter: then she would know cassie can always afford the life-saving medicine shall need. roxana saberi, cbs news, mechanicsville, virginia. >> norah: "heart of america" is next with a heartwarming story about an incredible family reunion months after the devastating maui wildfires. detect this: living with hiv, robert learned he can stay undetectable with fewer medicines. that's why he switched to dovato. dovato is a complete hiv treatment for some adults. no other complete hiv pill uses fewer medicines to help keep you undetectable than dovato. detect this: marnina learned that most hiv pills contain 3 or 4 medicines. dovato is as effective with just 2. if you have hepatitis b, don't stop dovato without talking to your doctor. don't take dovato if you're allergic to its ingredients or taking dofetilide. this can cause serious or life-threatening side effects. if you have a rash or allergic reaction symptoms, stop dovato and get medical help rig

eli lilly says it supports bipartisan federal legislation capping prices at $35 for everyone.> every insulin should have a cap. >> reporter: then she would know cassie could always afford the life-saving medicine she'll need. roxana saberi, cbs news, mechanicsville, virginia. >> norah: "heart of america" is next with a heartwarming story about an incredible family reunion months after the devastating maui wildfires. meet mahina, she was missing for . detect this: living with hiv, robert learned he can stay undetectable with fewer medicines. that's why he switched to dovato. dovato is a complete hiv treatment for some adults. no other complete hiv pill uses fewer medicines to help keep you undetectable than dovato. detect this: marnina learned that most hiv pills contain 3 or 4 medicines. dovato is as effective with just 2. if you have hepatitis b, don't stop dovato without talking to your doctor. don't take dovato if you're allergic to its ingredients or taking dofetilide. this can cause serious or life-threatening side effects. if you have a rash or allergic reaction symptoms

eli lilly up 25%. merck is up 15%. let's talk more with mark goldstein at mizuho. >> good morning. thanks for having me. >> great to have you here. right now, we're seeing healthcare hitting a new high. it was a laggard last year. why is healthcare getting so much investor interest and moving higher? >> i think you have a couple of combination of factors. some are specific to the overall macro environment. first of all, the idea of lower interest rates are better or certainly healthcare. you have that. i think you add in a little more clarity on what the political environment might be like over the next few years. that is always important to health care stocks. you combine with a sector that was beaten down and over sold and beaten down and that means the stocks are up well. >> obviously, the sector is performing well. we mentioned hitting a high. your top pick in the space is merck. what is it about merck that makes it the top pick? >> we have a particularly unique focus within the coverage. we focus heavily on oncology. it is not its only sector. what we like abo